Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7400-0.4800 (-9.20%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.2200
Open5.1600
Bid4.7000 x 1100
Ask4.8100 x 1100
Day's Range4.6940 - 5.2700
52 Week Range2.2300 - 6.8800
Volume900,612
Avg. Volume3,089,374
Market Cap209.443M
Beta (5Y Monthly)0.74
PE Ratio (TTM)N/A
EPS (TTM)-1.3100
Earnings DateOct 27, 2021 - Nov 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.24
  • Benzinga

    InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder

    InflaRx N.V. (NASDAQ: IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV). The trial demonstrated a comparable clinical response of vilobelimab to the standard of care, significantly reducing the need for glucocorticoid (GC) treatment. Clinical response at week 16 in evaluable patients was observed in 16 out of 18 patients in the treatment group receiving vilobelimab alone; in 22 out of 23 patients receiving a standa

  • GlobeNewswire

    InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)

    Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients: vilobelimab demonstrated comparable efficacy to standard of careUse of vilobelimab instead of glucocorticoids led to a substantially lower observed glucocorticoid toxicityVilobelimab demonstrated a good safety and tolerability profile; vilobelimab only treatment arm had lowest number of reported treatment emergent adverse events JENA, Germany, Nov. 15, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V.

  • GlobeNewswire

    InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference

    JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will present a corporate overview at the H.C. Wainwright 7th Annual Israel Conference. The session will take place virtually on Monday, November 15th at 8:00 am EST/2:00 pm CET and can be accessed via a live web

Advertisement
Advertisement